Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Net Income towards Common Stockholders data on file, last reported at $164.5 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 327.74% year-over-year to $164.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $774.7 million (up 371.06% YoY) and the FY2025 annual result came in at $313.7 million, up 212.79% from the prior year.
• Net Income towards Common Stockholders declined to $164.5 million in Q2 2026, from $206.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $292.7 million in Q3 2025 to a low of -$405.9 million in Q3 2022.
• A 5-year average of -$64.7 million and a median of -$78.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders sank 327.66% — and 2026, when it soared 1228.66%.
• Tracing ALNY's Net Income towards Common Stockholders over 5 years: stood at -$207.5 million in 2022, then soared by 33.55% to -$137.9 million in 2023, then soared by 39.24% to -$83.8 million in 2024, then jumped by 233.17% to $111.5 million in 2025, then surged by 47.47% to $164.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $164.5 million (Q2 2026), $206.0 million (Q1 2026), and $111.5 million (Q4 2025), per Business Quant data.